^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Pancreatic Ductal Adenocarcinoma

Related cancers:
13h
CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, Anup Kasi | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
14h
Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. (PubMed, Mol Cancer Ther)
Furthermore, CD8+ T cells and T1IFN signaling were required for therapeutic efficacy as host depletion of CD8+ T cells or the T1IFN receptor diminished treatment responses. Overall, our results indicate that olaparib enhances radiation-induced T1IFN-mediated immune signaling and subsequently an adaptive immune response, thus sensitizing pancreatic cancer to αPD-L1 therapy, supporting an ongoing clinical trial of this therapy in patients with PDAC.
Journal
|
CD8 (cluster of differentiation 8)
|
Lynparza (olaparib)
16h
AXL-TBK1 driven AKT3 activation promotes metastasis. (PubMed, Sci Signal)
In human pancreatic ductal adenocarcinoma tissue, nuclear AKT3 colocalized with Snail and correlated with worse clinical outcomes. Primary mouse pancreatic cancer cells deficient in AKT3 showed reduced metastatic spread in vivo, suggesting selective AKT3 inhibition as a potential therapeutic avenue for targeting EMT in aggressive cancers.
Journal
|
AXL (AXL Receptor Tyrosine Kinase)
19h
Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports. (PubMed, Front Immunol)
In each case, checkpoint blockade led to durable radiographic responses. We therefore propose that it is reasonable to assess combined positive score and tumor mutational burden in refractory or recurrent pancreatic cancers when initiation of ICB is being considered.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression
|
Keytruda (pembrolizumab)
23h
A Role for Periostin Pathological Variants and Their Interaction with HSP70-1a in Promoting Pancreatic Cancer Progression and Chemoresistance. (PubMed, Int J Mol Sci)
Additionally, only pathological Pn-ASVs interacted with heat shock protein 70-1a (HSP70-1a), leading to significant rescue of gemcitabine-induced PDAC apoptosis. In silico analysis revealed that the presence or absence of exon 21 changes the tertiary structure of Pn and the binding sites for HSP70-1a. Altogether, Pn-ASVs with exon 21 secreted from CAFs play a key role in supporting tumor growth by interacting with cancer cell-derived HSP70-1a, indicating that Pn-ASVs with exon 21 might be a potential therapeutic and diagnostic target in PDAC patients with rich stroma.
Journal
|
POSTN (Periostin)
|
gemcitabine
23h
Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas. (PubMed, Int J Mol Sci)
Our data suggest that IPMN-derived and PanIN-derived PDACs differ in the expression of immune profiles and metabolic pathways. These initial findings warrant validation and follow-up to develop biomarker-based strategies for early PDAC detection and treatment.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • MUC2 (Mucin 2)
1d
HOXA11-As Promotes Lymph Node Metastasis Through Regulation of IFNL and HMGB Family Genes in Pancreatic Cancer. (PubMed, Int J Mol Sci)
Moreover, HMGB3 knockdown suppressed proliferation and migration by PDAC cells. These results suggest that HOXA11-AS contributes to PDAC progression, at least in part, through regulation of IFNL and HMGB family genes and that HOXA11 AS is a potential therapeutic target in PDAC.
Journal
|
HOXA11 (Homeobox A11) • HOXA11-AS (HOXA11 Antisense RNA)
1d
Characterization of Epithelial-Mesenchymal and Neuroendocrine Differentiation States in Pancreatic and Small Cell Ovarian Tumor Cells and Their Modulation by TGF-β1 and BMP-7. (PubMed, Cells)
Likewise, in BIN-67 cells, BMP-7 was able to reduce proliferation, while in SCCOHT-1 cells this occurred only upon combined treatment with TGF-β and BMP-7. We conclude that in PDAC-derived tumor cells, NED is closely linked to EMT and TGF-β signaling, which may have implications for the therapeutic use of TGF-β inhibitors in PDAC management.
Journal • Tumor cell
|
CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • SSTR5 (Somatostatin Receptor 5) • SNAI1 (Snail Family Transcriptional Repressor 1) • SYP (Synaptophysin) • CHGA (Chromogranin A) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
|
CDH1 expression • VIM expression
1d
Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications. (PubMed, Cancers (Basel))
SIRT1 influences apoptosis and chemoresistance through hypoxia, enhancing glycolytic metabolism and HIF-1α signaling, which sustain tumor survival against drugs like gemcitabine...This review meticulously explores the nuanced involvement of sirtuins in pancreatic cancer, elucidating their contributions to tumorigenesis and suppression through mechanisms such as metabolic reprogramming, the maintenance of genomic integrity and epigenetic modulation. Furthermore, it emphasizes the urgent need for the development of targeted therapeutic interventions aimed at precisely modulating sirtuin activity, thereby enhancing therapeutic efficacy and optimizing patient outcomes in the context of pancreatic malignancies.
Review • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • SIRT3 (Sirtuin 3) • SIRT1 (Sirtuin 1) • SIRT6 (Sirtuin 6) • SIRT4 (Sirtuin 4) • SIRT5 (Sirtuin 5) • SIRT7 (Sirtuin 7)
|
gemcitabine
2d
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. (PubMed, Clin Cancer Res)
IHC stratification of primary tumors by HMGA2 and GATA6 status in pancreatic cancer is associated with differential outcomes, survival following chemotherapy, and tumor microenvironments. As a nuclear marker for basal disease, HMGA2 complements GATA6 to identify disease subtypes in PDAC.
Journal
|
CD8 (cluster of differentiation 8) • GATA6 (GATA Binding Protein 6) • HMGA2 (High mobility group AT-hook 2)
|
HMGA2 expression
|
gemcitabine
2d
Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report. (PubMed, World J Gastrointest Oncol)
Mixed NET/non-NET tumors with distinct histology and molecular profiles might be better classified as collision tumors rather than MiNENs.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
|
TP53 mutation • KRAS mutation • TP53 mutation + KRAS mutation • KRAS mutation + TP53 mutation
2d
Isolation and characterization of microbiota from human pancreatic tumors and small intestine. (PubMed, bioRxiv)
We found that UMKO1 possesses a gene for the long form of cytidine deaminase, which can inactivate the standard PDAC chemotherapeutic agent gemcitabine...We found that while none of the bacterial supernatants changed the abundance of CD8 T cells, granzyme B positive CD8 T cells were the lowest in tumor explants exposed to UMKO1 , and not other isolated Klebsiella species or the non-pathogenic laboratory strain E. coli K12 . In summary, the isolated collection of bacteria and fungi from this study are a valuable toolbox to study the impact of microbiota on pancreatic cancer.
Journal
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
|
CD8 positive
|
gemcitabine
2d
The close association of Muribaculum and PA (10:0/a-17:0) with the occurrence of pancreatic ductal adenocarcinoma and immunotherapy. (PubMed, Front Immunol)
Furthermore, PA (10:0/a-17:0) demonstrated a strong correlation with PDAC immunotherapy outcomes (Rho: 0.758; P=0.011). These findings suggest that the biliary microbiota and associated metabolites play a crucial role in the development of PDAC and may serve as potential predictive biomarkers and therapeutic targets for disease management.
Retrospective data • Journal • IO biomarker
|
CA 19-9 (Cancer antigen 19-9)
2d
Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicenter Study. (PubMed, Ann Surg)
The ChemoResist signature could precisely predict survival in PDAC undergoing resection and chemotherapy, and its predictive value surpassed TNM stage and other clinicopathologic factors. Moreover, the ChemoResist classifier could assist with identifying patients who would more likely benefit from adjuvant chemotherapy.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog)
|
MTOR mutation
2d
Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best? (PubMed, Ann Surg)
CA19-9 response to NAT alone is not enough to identify long-term post-resection PDAC survivors. The co-existence of CA19-9 and major pathologic response was predictive of the most optimal survival outcome.
Journal
|
CA 19-9 (Cancer antigen 19-9)
|
albumin-bound paclitaxel • irinotecan
3d
AK104-217: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
P2, N=78, Recruiting, Akeso | Not yet recruiting --> Recruiting | N=60 --> 78 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Kaitanni (cadonilimab)
4d
Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization. (PubMed, FASEB J)
Alterations in inflammatory signaling pathways occurred following KO cell exposure to CM containing sMSLN, and CM from cancer cells with intact peritoneal metastasis provoked increased KO cell secretion of IL-1α. While excess sMSLN inhibits cell clustering and peritoneal colonization, sMSLN may also promote PDAC peritoneal metastasis independent of MUC-16.
Journal
|
MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
|
MSLN expression
5d
Analyzing the high frequency of false-positive carcinoembryonic antigen elevations in postoperative pancreatic ductal adenocarcinoma. (PubMed, Langenbecks Arch Surg)
CEA may rise in more than half of postoperative PDAC patients without recurrence. CEA alone is not a robust postoperative marker.
Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 positive
5d
FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2027 --> Sep 2027
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
6d
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. (PubMed, Signal Transduct Target Ther)
An immune/metabolism score integrating the features of six genes was developed as a predictive biomarker for immunotherapy response in multiple cohorts, allowing for the selection of patients most likely to experience positive outcomes from this therapy regimen. In conclusion, our study provides proof-of-concept data supporting the potential of SHR-1701 plus famitinib as an effective and safe subsequent-line therapy for refractory BTC and PDAC, highlighting the promise of targeting PD-L1, TGF-β, and angiogenesis pathways simultaneously.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
6d
Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study. (PubMed, Ann Surg Oncol)
In IPMN-derived PDAC, the optimal cutoff for early recurrence is 10.5 months. Both CA19-9 and N stage predict early recurrence. Adjuvant chemotherapy is associated with survival benefit only for high-risk patients.
Clinical • Journal
|
CA 19-9 (Cancer antigen 19-9)
6d
An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum. (PubMed, J Gastroenterol)
Overall, this study identified several proteins, metabolites and lipids involved in various pathways including cholesterol and lipid metabolism to be changing in patients. In addition, we discovered a multi-analyte signature that could be further tested for detection of PDAC.
Journal
|
STAG2 (Stromal Antigen 2) • KRT18 (Keratin 18)
7d
A CNA-35-based high-throughput fibrosis assay reveals ORAI1 as a regulator of collagen release from pancreatic stellate cells. (PubMed, Matrix Biol)
In conclusion, our study introduces a robust in vitro assay for fibrosis and identifies ORAI1 as being engaged in PSC-driven fibrosis.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • RAI1 (Retinoic Acid Induced 1)
7d
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. (PubMed, Sci Adv)
SRC inhibitors (DGY-06-116, dasatinib, and bosutinib) also exhibit synergistic effects with MRTX849 in eliminating various tumor cell lines carrying KRAS-G12C mutations. Thus, SRC inhibitors amplify the therapeutic utility of G12Ci.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
KRAS mutation • KRAS G12C • ABCC1 expression
|
dasatinib • Bosulif (bosutinib) • Krazati (adagrasib)
7d
Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasion. (PubMed, J Gastroenterol)
Our findings identify M2BPGi as a promising prognostic biomarker for PDAC. Moreover, we demonstrate that inflammatory CAFs promote tumor invasion and contribute to poor outcomes by secreting M2BPGi, revealing a novel mechanism of PDAC progression.
Journal
|
LGALS3BP (Lectin galactoside-binding soluble 3-binding protein)
7d
Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas. (PubMed, Cancer Med)
A differential gene expression profile between PDAC arising from IPMN and IPMN alone was identified. Pathway analysis identified potential mechanisms involved in malignant transformation of IPMN to PDAC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • THBS2 (Thrombospondin 2)
7d
Establishment and analysis of a prognostic model of pancreatic ductal adenocarcinomas based on nerve-cancer crosstalk-related genes. (PubMed, Int J Clin Exp Pathol)
Furthermore, the NGFR gene was shown to be more significantly expressed in various pancreatic cancer cells. Bioinformatics analysis was used to create a validated prognostic model of pancreatic cancer, which explored the critical mechanisms of neural-tumor interactions and revealed the potential of cancer-neural crosstalk-related genes as prognostic biomarkers and anti-tumor therapy targets.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NGFR (Nerve Growth Factor Receptor)
8d
Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma. (PubMed, Oncogene)
While a novel TF-ADC (MRG004A) demonstrated efficacy for PDAC and TNBC in a Phase I/II trial [Ref...Thus, TF-inhibition reshapes an "immune hot" tumor environment. TF-targeted therapy warrants clinical investigation as a single agent or in combination with immunotherapy for treating TF-positive PDAC and TNBC.
Journal • IO biomarker
|
CXCL9 (Chemokine (C-X-C motif) ligand 9) • STING (stimulator of interferon response cGAMP interactor 1)
|
MRG004A
8d
Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. (PubMed, Cell Oncol (Dordr))
Collectively, our data illustrate that CA9 has a direct regulatory role in pHi homeostasis and ROS production, providing a potential therapeutic target for PDAC treatment.
Journal
|
CA9 (Carbonic anhydrase 9) • FUS (FUS RNA Binding Protein) • NOX4 (NADPH Oxidase 4)
|
CA9 expression
8d
Survival of Patients with Resected Microsatellite Instability-High, Mismatch Repair Deficient, and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas. (PubMed, Ann Surg Oncol)
Before routine use of immune checkpoint inhibitors, the patients with MSI-H, MMRd, and LS-associated PDACs displayed significantly better survival than the patients with MSS, MMR-proficient, non-LS-associated PDACs. It is expected that survival for this cohort will further improve with increased availability of immunotherapy.
Journal • Mismatch repair • Microsatellite instability • MSi-H Biomarker • IO biomarker
|
MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
MSI-H/dMMR
8d
WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. (PubMed, J Gastroenterol)
WWP1 inhibition enhances the anti-tumor effects of PI3K-AKT pathway inhibitors through PTEN activation. Thus, WWP1 could be a potential therapeutic target in PDAC.
Journal
|
PTEN (Phosphatase and tensin homolog)
8d
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. (PubMed, Elife)
We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.
Journal
|
CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • NKG2D (killer cell lectin like receptor K1)
8d
Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study. (PubMed, Biomark Med)
Moreover, KRAS expression was shown to be significantly associated with perineural invasion (p = 0.005). This is the first study that investigates protein biomarker expression in a large cohort of Pakistani PDAC patients. The findings from the study may provide directions about the population specific biomarkers and targeted therapies for these patients.
Retrospective data • Journal • BRCA Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset)
|
TP53 expression • BRCA1 expression
9d
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P2, N=35, Completed, HonorHealth Research Institute | Active, not recruiting --> Completed | N=10 --> 35 | Trial completion date: Dec 2023 --> Mar 2024
Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
|
MUC16 (Mucin 16, Cell Surface Associated)
|
Opdivo (nivolumab) • cisplatin • gemcitabine • albumin-bound paclitaxel
9d
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
P1/2, N=46, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Completed | N=30 --> 46 | Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
9d
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. (PubMed, MAbs)
By combining TR2/CDH3 BAB with chemotherapeutic agents, deeper and more sustained anti-tumor responses were observed when compared to monotherapy. Together with the potential to deliver a favorable safety profile, these data support clinical testing of TR2/CDH3 BAB in patients with PDAC.
Journal
|
CDH3 (Cadherin 3) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
9d
Genetic Variation in Cyclin-Dependent Kinase Inhibitor 2A Associated with Increased Pancreatic Cancer Risk. (PubMed, Iran Biomed J)
The latter group of cases with a recessive genetic pattern (GG vs. GC+ CC) showed enhanced susceptibility to promoting PDAC (OR = 1.7; 95% CI: 1.2-2.9; p = 0.04). Our findings indicate that genetic variation in CDKN2A was linked to the susceptibility of extending PDAC, suggesting the need for additional research in a broader, multi-center context to approve the possible significance of this gene as a novel indicator for the stratification of PDAC.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD22 (CD22 Molecule) • MIR363 (MicroRNA 363) • BMF (Bcl2 Modifying Factor)
9d
Quantitative MRI Measurements Capture Pancreatic Cancer and Stroma Reactions to New KRAS Inhibitor. (PubMed, bioRxiv)
We tested this hypothesis in multiple preclinical PDAC models receiving MRTX1133, an investigational new drug specific for KRAS G12D mutation...Our data demonstrate the abilities of DWI, DCE and MTR derived imaging markers to detect the early (48h) cell death, pronounced stromal changes and development of resistance to KRASi. This study has high translational relevance by testing clinically ready MRI methods, an IND and a genetic engineered mouse model that recapitulates saline features of human PDAC.
Journal • Stroma
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12
|
MRTX1133
9d
Paired CRISPR screens to map gene regulation in cis and trans. (PubMed, bioRxiv)
Finally, we show that expression of these TFs correlates with PD-L1 expression in vivo in primary PDAC tumors and that somatic mutations in TFs can alter response and overall survival in immune checkpoint blockade-treated patients. Taken together, our approach establishes a generalizable toolkit for decoding the regulatory landscape of any gene or locus in the human genome, yielding insights into gene regulation and clinical impact.
Journal • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma)
|
PD-L1 expression
9d
miR-210 Mediated Hypoxic Responses in Pancreatic Ductal Adenocarcinoma. (PubMed, ACS Omega)
Understanding the regulatory network involving miR-210 under hypoxic conditions may reveal new therapeutic targets for combating PDAC and improving patient outcomes. Our data suggest that miR-210 is a critical regulator of HIF1-α expression, EMT, and the stemness of PDAC cells in hypoxic environments.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CDH1 (Cadherin 1) • CD24 (CD24 Molecule) • VIM (Vimentin) • MIR210 (MicroRNA 210)
|
HIF1A expression
9d
Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma. (PubMed, Cancer Commun (Lond))
We revealed the crosstalk between platelets and tumor cells in the liver metastatic niche of PDAC. Reciprocal tumor-platelet interaction mediated by the EPHB1-EFNB1 reverse signaling promoted metastatic PDAC outgrowth via 5-HT in the liver. Interfering the tumor-platelet interaction by targeting the EPHB1-EFNB1 axis may represent a promising therapeutic intervention for PDAC liver metastasis.
Journal • Metastases
|
EPHB1 (EPH Receptor B1)
10d
Trial completion • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
S95024 • Sym021